Fc epsilon RI alpha / IgE Fc Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Prostate cancer vaccine (Advaxis) | ADXS-PSA; ADXS-31142 | Phase 2 Clinical | Advaxis Inc | Neoplasms; Prostatic Neoplasms | Details |
| TP-122A | TP-122A | Phase 2 Clinical | Vector B2B, Technophage SA | Pneumonia, Ventilator-Associated | Details |
| GEA-408 | GEA-408 | Phase 2 Clinical | GenEros Biopharma Hangzhou Ltd | Prostatic Neoplasms | Details |
| P-PSMA-101 | P-PSMA-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Genital Neoplasms, Male; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Urogenital Neoplasms; Prostatic Diseases | Details |
| Prostate cancer subunit vaccine (Progenics) | Phase 1 Clinical | Progenics Pharmaceuticals Inc | Prostatic Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Afala | Approved | Materia Medica Holding Research And Production Company | Russian Federation | Prostatic Neoplasms; Prostatitis | Materia Medica Holding Research And Production Company | 2014-01-01 | Prostatic Neoplasms; Prostatitis | Details |